Clinical trials: Differentiated Thyroid Carcinoma
Differentiated Thyroid Cancer
rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)
This study was conducted in patients with differentiated thyroid cancer who had undergone total/near-total thyroidectomy. After surgery patients were randomized to one of two methods of performing thyroid remnant ablation.
- Trial name
- NCT04964284
- Testing
- rhTSH, Radioiodine (131I)
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Thyroid Cancer Patients
Effect of Carum Carvi on Thyroid Hormones and TSH Level
Carum Carvi has been frequently used in traditional medicine for a variety of disease ranging from dyspepsia to Alzheimer's disease.We observed high TSH levels in few patients with thyroid cancer who receiving Carum Carvi despite…
- Trial name
- NCT01471288
- Testing
- Carum Cravi
- Where
- Iran
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mashhad University of Medical Sciences
Thyroid Cancer
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyroid cancer (DTC)…
- Trial name
- NCT00784303
- Testing
- Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Inc.
Differentiated Thyroid Cancer, Pediatric Cancer
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy.
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Trial name
- RAISE (NCT06458036)
- Testing
- Selpercatinib Monotherapy, 131I Therapy
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Thyroid
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
This pilot clinical trial studies how will metformin hydrochloride works in mitigating the side effects of radioactive iodine treatment in patients with differentiated thyroid cancer.
- Trial name
- NCT03109847
- Testing
- Metformin Hydrochloride, Radioactive Iodine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Malignant Neoplasm of Thyroid, Heart Diseases
Thyrotropin Over-suppression and Heart
The investigators evaluated the cardiac effects of Thyroid-stimulating hormone (TSH) over-suppression in women with differentiated thyroid cancer (DTC) frequently encountered during suppression therapy.
- Conditions
- Malignant Neoplasm of Thyroid, Heart Diseases, Thyrotoxicosis on Thyroxine Therapy
- Trial name
- NCT02645786
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Thyroid Cancer, Metastases
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
Metastases of thyroid cancer with iodine uptake are treated with repeated activity of I-131 administered after thyroid hormone withdrawal.
- Trial name
- DOSIMETA (NCT01403324)
- Testing
- TSH stimulation
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Radioiodine Refractory Differentiated Thyroid Cancer
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
177Lu-LNC1004 Injection, a radiopharmaceutical targeting FAP, has demonstrated preliminary antitumor effect in advanced FAP-positive solid tumor patients.
- Trial name
- NCT06898437
- Testing
- 177Lu-LNC1004 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00104871
- Testing
- Bortezomib
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Carcinoma (DTC), Neoadjuvant Therapy
Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
This study is a single-arm, prospective investigation aimed at evaluating the efficacy of Sinibolimab combined with Lenvatinib as neoadjuvant therapy for locally advanced unresectable differentiated thyroid carcinoma in a Phase…
- Trial name
- NCT06848920
- Testing
- Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Differentiated Thyroid Cancer
Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy
Radiofrequency (RF) could be technically feasible and effective in the treatment of lymph node metastases of differentiated thyroid cancer.
- Trial name
- METATHYRAF (NCT03416686)
- Testing
- Radiofrequency (RF star electrode electrode_Fixed)
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Differentiated Thyroid Cancer, Advanced Cancer
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC).
- Trial name
- NCT04321954
- Testing
- LENVATINIB
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Cancer, Thyroid Carcinoma
Thyroid Cancer and Sunitinib
Due to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this…
- Trial name
- THYSU (NCT00510640)
- Testing
- Sunitinib
- Where
- 15 sites in France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Thyroid Cancer
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
This is a Phase 2 Study of Everolimus and Lenvatinib in patients with metastatic differentiated thyroid cancer who have progressed on lenvatinib alone. Patient will have imaging, lab test and physical exams
- Trial name
- NCT03139747
- Testing
- Lenvatinib, Everolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Thyroid Cancer, Thyroid Neoplasms
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
- Trial name
- IoN (NCT01398085)
- Testing
- I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation
- Where
- 36 sites in United Kingdom
- Volunteers
- 504 people
- Sponsor
- University College, London
Thyroid Neoplasms
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.
- Trial name
- NCT00279721
- Testing
- IMRT
- Volunteers
- 40 people
- Sponsor
- Alberta Health services
Thyroid Cancer
GETNE Registration of Thyroid Cancer
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
- Trial name
- NCT03765333
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos